- Home
- JFU vs AIMD Comparison
JFU vs AIMD Comparison
Compare JFU & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- AIMD
- Stock Information
- Founded
- JFU 2006
- AIMD 1984
- Country
- JFU China
- AIMD United States
- Employees
- JFU N/A
- AIMD N/A
- Industry
- JFU Finance: Consumer Services
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- AIMD Health Care
- Exchange
- JFU Nasdaq
- AIMD Nasdaq
- Market Cap
- JFU 17.1M
- AIMD 16.9M
- IPO Year
- JFU 2019
- AIMD N/A
- Fundamental
- Price
- JFU $2.51
- AIMD $3.51
- Analyst Decision
- JFU
- AIMD
- Analyst Count
- JFU 0
- AIMD 0
- Target Price
- JFU N/A
- AIMD N/A
- AVG Volume (30 Days)
- JFU 27.5K
- AIMD 173.2K
- Earning Date
- JFU 01-01-0001
- AIMD 11-05-2025
- Dividend Yield
- JFU N/A
- AIMD N/A
- EPS Growth
- JFU N/A
- AIMD N/A
- EPS
- JFU 0.58
- AIMD N/A
- Revenue
- JFU $42,467,427.00
- AIMD $110,870.00
- Revenue This Year
- JFU N/A
- AIMD N/A
- Revenue Next Year
- JFU N/A
- AIMD N/A
- P/E Ratio
- JFU $4.36
- AIMD N/A
- Revenue Growth
- JFU N/A
- AIMD 70.25
- 52 Week Low
- JFU $1.01
- AIMD $2.00
- 52 Week High
- JFU $3.60
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- JFU 69.35
- AIMD 51.80
- Support Level
- JFU $2.31
- AIMD $3.56
- Resistance Level
- JFU $3.25
- AIMD $3.81
- Average True Range (ATR)
- JFU 0.25
- AIMD 0.25
- MACD
- JFU 0.02
- AIMD -0.03
- Stochastic Oscillator
- JFU 47.52
- AIMD 25.27
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.